Datamonitor reviews recent pharmacoeconomic evaluations of drug treatments for Alzheimer's disease with a particular focus on methodology and study design. Components of the studies are critically reviewed with regards to the optimal approach to perfoming economic analyses in Alzheimer's disease. The Brief presents the opportunities available to drug manufacturers to maximize the commercial benefits offered by the use of pharmacoeconomics in all stages of the Alzheimer's disease product lifecycle.
